SLC7A11-IN-1 is an SLC7A11 inhibitor with anti-proliferative and anti-cancer activities. It inhibits cell invasion and metastasis, induces apoptosis and cell cycle arrest. It can be used for research on neurodegenerative diseases.

MCF-7 cells:0.18 µM, HCT116 cells:0.03 µM, HepG2 cells:0.17 µM, L02 cells:0.27 µM, MDA-MB-231 cells:0.11 µM

SLC7A11-IN-1 (compound 2) (0-100 µM; 72 hrs of action) exhibited antiproliferative activity against a variety of cell lines with IC50 values of HCT-116: 0.03 µM, MDA-MB-231: 0.11 µM, MCF-7: 0.18 µM, HepG2: 0.17 µM, LO2: 0.27 µM.[1]
SLC7A11-IN-1 (0.5 µM, treated for 24 h) inhibited the invasive and migratory abilities of HCT-116 cells, triggered apoptosis, and arrested the cell cycle in S-phase, as well as significantly reduced intracellular GSH levels, while significantly increasing the expression of reactive oxygen species (ROS). [1]
SLC7A11-IN-1 (1 µM, 15 hr treatment) significantly induced DNA damage in HCT-116 cells and upregulated the expression of related proteins. [1]

SLC7A11-IN-1 (2 mg/kg via tail vein injection every three days for three consecutive times) exhibited tumor growth inhibition in mice. [1]

DMSO: 16 mg/mL (24.08 mM), Sonication is recommended.